Tryp Therapeutics has announced that it has enrolled its first patient in its Phase II clinical trial evaluating its clinical candidate, TRP-8802. The study will investigate the safety and preliminary effectiveness of psilocybin-assisted therapy among patients with binge eating disorders in collaboration with the University of Florida.
Category Press Release
Published in Tryp Therapeutics
Companies Featured
Tryp TherapeuticsTryp Therapeutics is a clinical stage drug development company developing psilocybin products for various diseases/disorders including fibromyalgia.
Trials Linked
Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating DisorderTo better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 (psilocybin) among individuals with Binge Eating Disorder.